Array Bio (ARRY) Trading Lower as UBS Downgrades from Buy to Neutral; Shares Down Over 5%
Tweet Send to a Friend
Array Biopharma (Nasdaq: ARRY) is down about 5.3% to $3.74 after UBS is lowered their rating from Buy to Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
